Objective: To report all pregnancies to date after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for the conservative treatment of clinically significant uterine fibroids.
Design: Prospective registry of all known pregnancies occurring after MRgFUS maintained by the device manufacturer and reported to the Food and Drug Administration.
Setting: World experience of pregnancies after treatment with reports from 13 sites in seven countries.
Patient(s): Fifty-one reproductive-age women with uterine leiomyomas.
Intervention(s): Women underwent MRgFUS treatment for symptomatic uterine leiomyomas before this report.
Main outcome measure(s): Pregnancy outcomes and complications.
Result(s): Fifty-four pregnancies in 51 women have occurred after MRgFUS treatment of uterine leiomyomas. The mean time to conception was 8 months after treatment. Live births occurred in 41% of pregnancies, with a 28% spontaneous abortion rate, an 11% rate of elective pregnancy termination, and 11 (20%) ongoing pregnancies beyond 20 gestational weeks. The mean birth weight was 3.3 kg, and the vaginal delivery rate was 64%.
Conclusion(s): Preliminary pregnancy experience after MRgFUS is encouraging, with a high rate of delivered and ongoing pregnancies.
Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.